– ISRAEL, Or-Yehuda – VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Marc Kozin as Vice-Chairman of its Board of Directors. Mr. Kozin will transition to becoming Chairman during 2021, at which time the current Board Chairman, Dr. Bennett Shapiro will step down as Chairman while remaining a member of the Board of Directors.
“I am very happy to pass the role to Marc as the next generation, and believe he is very well qualified to lead the company to fulfill its mission and bring our unique novel drug, VB-111 to cancer patients.” said Board Chairman, Dr. Bennett Shapiro.
He added: “I have had the honor of serving as the Chairman of VBL’s Board of Directors for many years, during a period in which the company had significant accomplishments and transitioned from R&D to late clinical-stage”
CEO, Dr. Dror Harats commented, “Marc has an exceptional track record of helping biotech companies navigate to success. As VBL continues to evolve and as we get ready to provide patients in need with access to our Phase 3 anti-cancer therapy, VB-111, it is important to have Board members with the appropriate areas of expertise. Marc brings extensive professional, strategic, and financial experience, as demonstrated by his leadership roles with companies that have achieved success and significant value creation. We are confident that he will make important contributions to our company.”
Dr. Harats concluded, “I would like to thank Dr. Shapiro for his leadership and I am pleased that he will continue to serve on our Board of Directors.”
About Marc Kozin
Marc Kozin has three decades of industry expertise advising biopharmaceutical, life sciences, and MedTech companies. He is currently the Chairman of the Strategy Advisory Board of HealthCare Royalty Partners, a leading investment firm in healthcare, providing royalty monetization and senior debt. Previously, Mr. Kozin was a career strategy consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 to 2012. He began his career at L.E.K. in 1987 by helping establish the Boston office and led the development of L.E.K.’s industry-leading life science strategic planning practice.
Mr. Kozin has served on over a dozen Boards in a variety of roles and on all committees. He is currently the Lead Independent Director and serves on the Compensation Committee of UFP Technologies (Nasdaq: UFPT). He serves as Director and Chairman of the Compensation Committee for Dicerna Pharmaceuticals (Nasdaq: DRNA). Previously, he served on the board of Endocyte, helping the company negotiate a $2.1 billion M&A deal with Novartis. He was also a board member of Dyax which was acquired by Shire in 2015 for $6.5 billion. Mr. Kozin has served as Director of The Greenlight Fund, a non-profit focused on improving the lives of inner-city children in families, since 2017. He was also on the Board of Governors at New England Medical Center and the Board of DukeEngage for several years.
Marc Kozin said, “This is an exciting time for VBL, as evidenced by the excellent progress in the ongoing OVAL trial of VB-111 in ovarian cancer, the expansion of VB-111 into new oncology indications and advancement of the pipeline. I believe that VBL is well-positioned to deliver on its mission to commercialize first-in-class treatments in cancer and immune/inflammatory indications and I look forward to contributing to the Company’s success.”
He received a BS in Economics from Duke University in 1983 and an MBA in Finance from The Wharton School in 1987.
About VBL
Vascular Biogenics Ltd., dba as VBL Therapeutics, is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with a focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec, is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all-comers” Phase 1 trial as well as in three VBL-sponsored tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.
For more information: https://www.vblrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
